May 28, 2024
April 29, 2024
selectION Announces Positive Results from Phase 1b Clinical Trial Evaluating si-544 in Patients with Atopic Dermatitis
January 5, 2024
selectION, Inc. to Present Update on Clinical Progress at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on January 11, 2024
June 2, 2023
selectION awaits efficacy data from trial of Kv1.3 ion channel blocker in atopic dermatitis
May 30, 2023
selectION, Inc., Reports Interim Safety and Tolerability Results of Phase 1b Clinical Trial in Atopic Dermatitis
November 29, 2022
Immusoft Receives $4M In Funding From The California Institute For Regenerative Medicine (CIRM)
October 17, 2022
Avalyn Pharma Appoints Lyn Baranowski Chief Executive Officer
September 12, 2022
selectION, Inc. Initiates Dosing in Atopic Dermatitis Patients
September 1, 2022
Immusoft Announces FDA Clearance Of IND Application For ISP-001 For MPS I, The First Engineered B Cell Therapy To Enter Into Clinical Trials
May 9, 2022